CanSino Biologics, Inc. Class A

As of June 30, 2024, CanSino Biologics, Inc. Class H carries a market capitalization of 1.80B, placing it among publicly traded companies globally. Its enterprise value stands at 1.63B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

CanSino Biologics, Inc. Class H's next confirmed earnings release is scheduled for October 27, 2026.

As of June 30, 2024, CanSino Biologics, Inc. Class H has 769.82M shares outstanding.

These figures are as of June 30, 2024. The price-to-sales ratio is 11.27, and the price-to-book ratio stands at 2.77.

These figures are as of June 30, 2024. The EV/Sales ratio of 20.83 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 1.63B versus a market cap of 1.80B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2024, CanSino Biologics, Inc. Class H maintains a current ratio of 2.38, meaning it holds 2.4x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 43.43, indicating elevated leverage, while an interest coverage ratio of -14.37 demonstrates limited ability to service its debt obligations.

Over the twelve months ended June 30, 2024, CanSino Biologics, Inc. Class H posted a negative return on equity (ROE) of -15.80, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -9.61, reflecting losses generated across the asset base. The company generates approximately 46,222.67 in revenue per employee across its workforce of 1,693.25, a quick read on workforce productivity versus industry peers. Inventory turnover of 1.28 indicates how many times CanSino Biologics, Inc. Class H sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2024, CanSino Biologics, Inc. Class H recorded an income tax benefit of -1.20M rather than an expense, typically from losses, carryforwards, or the release of a tax provision. The company reported a pretax loss of -118.74M and -111.29M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 22, 2026, CanSino Biologics, Inc. Class H's stock has declined approximately 32.47% over the past 52 weeks. The 50-day moving average sits at 3.39, while the 200-day moving average is 3.27.

Over the twelve months ended June 30, 2024, CanSino Biologics, Inc. Class H generated 78.27M in revenue and converted that into -111.29M in net income, yielding earnings per share of -0.31. EBITDA reached -124.73M, while operating income came in at -118.21M.

As of June 30, 2024, CanSino Biologics, Inc. Class H holds 453.09M in cash and equivalents against 282.13M in total debt, resulting in a net debt position of 58.26M. Total book value stands at 649.68M, with working capital of 337.83M providing operational flexibility.

These figures cover the twelve months ended June 30, 2024.

Over the twelve months ended June 30, 2024, CanSino Biologics, Inc. Class H posted a gross margin of 14.38, reflecting its pricing power and cost economics. The operating margin of -151.03 and net profit margin of -142.19 provide insight into operational efficiency.

Over the twelve months ended June 30, 2024, CanSino Biologics, Inc. Class H paid dividends of - - per share. The dividend payout ratio of - - indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Total shareholder yield is negative at -0.72, meaning CanSino Biologics, Inc. Class H raised more capital through share issuance and new debt than it returned via dividends and buybacks.

As of June 30, 2024, CanSino Biologics, Inc. Class H has an Altman Z-Score of 2.52, near the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.